WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 328203

CAS#: 4171-13-5

Description: Valnoctamide (MI-181) is a chiral constitutional isomer of valproic acid. It is a mild tranquilizer endowed with anticonvulsant properties, suggesting it may be an alternative treatment for epilepsy and bipolar disorder. Valnoctamide does not show any teratogenic effect, even when used in relatively high dosages.

Price and Availability


USD 190

USD 350

USD 550

Valnoctamide, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide).

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 328203
Name: Valnoctamide
CAS#: 4171-13-5
Chemical Formula: C8H17NO
Exact Mass: 143.131
Molecular Weight: 143.23
Elemental Analysis: C, 67.09; H, 11.96; N, 9.78; O, 11.17

Synonym: Valnoctamide; MI181; MI-181; MI 181

IUPAC/Chemical Name: 2-ethyl-3-methylpentanamide


InChi Code: InChI=1S/C8H17NO/c1-4-6(3)7(5-2)8(9)10/h6-7H,4-5H2,1-3H3,(H2,9,10)


Technical Data

White to off-white solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Wlodarczyk BJ, Ogle K, Lin LY, Bialer M, Finnell RH. Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice. Bipolar Disord. 2015 Sep;17(6):615-25. doi: 10.1111/bdi.12325. Epub 2015 Aug 20. PubMed PMID: 26292082; PubMed Central PMCID: PMC4631615.

2: Shekh-Ahmad T, Mawasi H, McDonough JH, Yagen B, Bialer M. The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Epilepsy Behav. 2015 Aug;49:298-302. doi: 10.1016/j.yebeh.2015.04.012. Epub 2015 May 13. Review. PubMed PMID: 25979572.

3: Mawasi H, Shekh-Ahmad T, Finnell RH, Wlodarczyk BJ, Bialer M. Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide--Amide derivatives of valproic acid. Epilepsy Behav. 2015 May;46:72-8. doi: 10.1016/j.yebeh.2015.02.040. Epub 2015 Apr 8. PubMed PMID: 25863940.

4: Modi HR, Basselin M, Rapoport SI. Valnoctamide, a non-teratogenic amide derivative of valproic acid, inhibits arachidonic acid activation in vitro by recombinant acyl-CoA synthetase-4. Bipolar Disord. 2014 Dec;16(8):875-80. doi: 10.1111/bdi.12220. Epub 2014 Jul 8. PubMed PMID: 25041123; PubMed Central PMCID: PMC4554599.

5: Spampanato J, Dudek FE. Valnoctamide enhances phasic inhibition: a potential target mechanism for the treatment of benzodiazepine-refractory status epilepticus. Epilepsia. 2014 Sep;55(9):e94-8. doi: 10.1111/epi.12702. Epub 2014 Jul 3. PubMed PMID: 24995528; PubMed Central PMCID: PMC4167227.

6: Shekh-Ahmad T, Hen N, McDonough JH, Yagen B, Bialer M. Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus. Epilepsia. 2013 Sep;54 Suppl 6:99-102. doi: 10.1111/epi.12290. PubMed PMID: 24001086.

7: Shekh-Ahmad T, Hen N, Yagen B, McDonough JH, Finnell RH, Wlodarczyk BJ, Bialer M. Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential. Epilepsia. 2014 Feb;55(2):353-61. doi: 10.1111/epi.12480. Epub 2013 Dec 6. PubMed PMID: 24313671; PubMed Central PMCID: PMC4963464.

8: Bersudsky Y, Applebaum J, Gaiduk Y, Sharony L, Mishory A, Podberezsky A, Agam G, Belmaker RH. Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. Bipolar Disord. 2010 Jun;12(4):376-82. doi: 10.1111/j.1399-5618.2010.00828.x. PubMed PMID: 20636634.

9: Kaufmann D, Yagen B, Minert A, Wlodarczyk B, Finnell RH, Schurig V, Devor M, Bialer M. Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. Neuropharmacology. 2010 Jun;58(8):1228-36. doi: 10.1016/j.neuropharm.2010.03.004. Epub 2010 Mar 15. PubMed PMID: 20230843.

10: Barel S, Yagen B, Schurig V, Soback S, Pisani F, Perucca E, Bialer M. Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. Clin Pharmacol Ther. 1997 Apr;61(4):442-9. PubMed PMID: 9129561.